Literature DB >> 3093891

T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses.

J M Zarling, W Morton, P A Moran, J McClure, S G Kosowski, S L Hu.   

Abstract

There is much interest in developing vaccines against acquired immune deficiency syndrome (AIDS), which is caused by a retrovirus termed human immunodeficiency virus (HIV). Isolates of this virus include human T-lymphotropic virus type III (HTLV-III), lymphadenopathy-associated virus (LAV), and AIDS-associated retrovirus (ARV). Several approaches towards the development of an AIDS vaccine result in the production of antibodies in subprimates. These methods involve the use of: antigens isolated from the AIDS virus; viral antigens expressed by transfected cells or by recombinant vaccinia viruses; and particular synthetic peptides of viral antigens. Because T-cell-mediated immunity (in addition to antibodies) is involved in resistance to diseases and death caused by various enveloped viruses, we sought to determine whether potential AIDS vaccines can induce T-cell responses against the AIDS virus. Here we report that immunization of non-human primates, Macaca fascicularis (macaques), with recombinant vaccinia viruses that express LAV envelope glycoproteins gp41 and gp110 results not only in the production of antibodies against the LAV envelope antigens but also in the generation of T-cells that proliferate and produce the lymphokine interleukin-2 (IL-2), in response to stimulation with purified LAV. We believe this is the first report demonstrating T-cell-mediated immunity to the virus that causes AIDS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093891     DOI: 10.1038/323344a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  25 in total

1.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

2.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Authors:  K B Cease; H Margalit; J L Cornette; S D Putney; W G Robey; C Ouyang; H Z Streicher; P J Fischinger; R C Gallo; C DeLisi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 3.  Use of vaccinia virus to express biopharmaceutical products.

Authors:  D E Hruby; G Thomas
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

4.  CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity.

Authors:  G Pantaleo; A De Maria; S Koenig; L Butini; B Moss; M Baseler; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Expression of envelope glycoproteins of human immunodeficiency virus by an insect virus vector.

Authors:  S I Hu; S G Kosowski; K F Schaaf
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

6.  Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Authors:  D E Lanar; J A Tine; C de Taisne; M C Seguin; W I Cox; J P Winslow; L A Ware; E B Kauffman; D Gordon; W R Ballou; E Paoletti; J C Sadoff
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

7.  Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus.

Authors:  S L Hu; J M Zarling; J Chinn; B M Travis; P A Moran; J Sias; L Kuller; W R Morton; G Heidecker; R E Benveniste
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

8.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

10.  The development of an AIDS vaccine: progress and promise.

Authors:  A S Fauci; P J Fischinger
Journal:  Public Health Rep       Date:  1988 May-Jun       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.